Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

Apr 21, 2020

SELL
$26.15 - $77.24 $106,195 - $313,671
-4,061 Closed
0 $0
Q4 2019

Feb 12, 2020

SELL
$60.18 - $154.77 $6,740 - $17,334
-112 Reduced 2.68%
4,061 $293,000
Q3 2019

Nov 07, 2019

SELL
$140.29 - $189.96 $2,525 - $3,419
-18 Reduced 0.43%
4,173 $585,000
Q2 2019

Aug 06, 2019

SELL
$157.85 - $183.09 $68,349 - $79,277
-433 Reduced 9.36%
4,191 $767,000
Q1 2019

May 06, 2019

SELL
$89.33 - $163.65 $29,032 - $53,186
-325 Reduced 6.57%
4,624 $735,000
Q4 2018

Feb 11, 2019

SELL
$81.94 - $139.71 $25,073 - $42,751
-306 Reduced 5.82%
4,949 $474,000
Q3 2018

Nov 14, 2018

BUY
$138.11 - $169.04 $66,430 - $81,308
481 Added 10.08%
5,255 $742,000
Q2 2018

Jul 30, 2018

BUY
$140.36 - $175.76 $323,950 - $405,654
2,308 Added 93.59%
4,774 $747,000
Q1 2018

Apr 16, 2018

BUY
$152.15 - $192.33 $155,953 - $197,138
1,025 Added 71.13%
2,466 $397,000
Q4 2017

Feb 09, 2018

SELL
$60.72 - $167.34 $400,387 - $1.1 Million
-6,594 Reduced 82.07%
1,441 $237,000
Q3 2017

Oct 26, 2017

SELL
$61.4 - $88.52 $39,725 - $57,272
-647 Reduced 7.45%
8,035 $501,000
Q2 2017

Aug 15, 2017

BUY
N/A
8,682
8,682 $691,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.